17ohp Compounded denied as non-formulary by Blue Cross Blue Shield?

Blue Cross Blue Shield's specific coverage criteria for 17ohp compounded are defined in its own published medical/coverage policy and the FDA-approved prescribing label. A successful appeal documents that your medical records satisfy each criterion those sources list — confirmed diagnosis, any required prior treatments (with dates and outcomes), and clinical severity. If the exact criteria weren't included with your denial, request them in writing; your appeal then maps each requirement to the matching fact in your chart.

## Why BCBS Denied This as Non-Formulary

Blue Cross Blue Shield maintains a formulary — a tiered list of covered drugs. Compounded 17-hydroxyprogesterone caproate is not a commercially manufactured FDA-approved product and therefore does not appear on standard formulary lists. BCBS's pharmacy benefit manager processes the claim, finds no matching NDC code, and issues a non-formulary denial automatically. This is a coverage-structure issue, not a clinical judgment about whether you need the medication.

Non-formulary denials are appealed through the formulary-exception process, which exists specifically to address situations where no formulary alternative is clinically appropriate. You do not need to accept a substitute if your prescriber can document why the formulary alternatives are inadequate for your specific situation.

## Federal Appeal Rights

• ACA §2719 external review: Formulary-exception denials that involve a medical-necessity or coverage determination are eligible for external review by an Independent Review Organization. File within the window in your denial notice — typically around four months from the denial date.
• ACA formulary-exception rights: Under federal rules, plans must have an exceptions process; medical necessity is a valid basis for a formulary exception.
• ERISA §503 (self-funded plans): Full and fair review with written reasoning required.
• Expedited review: Available when delay threatens health.

## Concrete Appeal Steps

1. Request BCBS's formulary-exception form and its written exception criteria. 2. Confirm which formulary-tier progesterone alternatives BCBS considers substitutes for this compound. 3. Have your prescriber document — specifically and clinically — why each listed alternative is not appropriate for your case. Generic statements are insufficient; the letter must address each alternative. 4. Submit the formulary-exception request alongside the internal appeal within your plan's deadline. 5. Escalate to external review if the exception is denied.

## Documentation to Gather

• Diagnosis confirmation: Obstetric records establishing the indication, including gestational and risk history.
• Prior-treatment history: Records of any formulary alternatives tried, with dates, doses, and documented outcomes or reasons they were not pursued.
• Clinical-severity documentation: Chart entries capturing the clinical rationale for why the compounded formulation — rather than a commercially available alternative — is medically necessary.
• Prescriber medical-necessity letter: Must address each formulary alternative and explain, with clinical specificity, why it is contraindicated, ineffective, or otherwise inappropriate for this patient.
• Compounding pharmacy documentation: A letter from the dispensing compounding pharmacy confirming the formulation, purity, and clinical purpose may strengthen the case.

## Criteria-Mapping Structure

| BCBS Formulary-Exception Criterion | Supporting Documentation | |---|---| | Copy each listed exception criterion from the BCBS policy | Chart note, prescriber letter paragraph, prior-treatment record | | Requirement that formulary alternatives were tried or contraindicated | Dates, outcomes, or documented clinical reasoning for each alternative |

Obtain BCBS's current formulary and exception policy for your specific plan — formularies change annually and vary by affiliate. Your prescriber's office can assist in identifying which policy version applies.